Compare TransMedics Group Inc (TMDX) vs Vanguard International High Dividend Yield ETF (VYMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Vanguard International High Dividend Yield ETF — how do they compare? TransMedics Group Inc trades at $74.3 (market cap $2.54B), while Vanguard International High Dividend Yield ETF trades at $101.33. The key difference: Vanguard International High Dividend Yield ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| TMDX | VYMI | |
|---|---|---|
Market Cap | $2.54B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $150.42 | $101.60 |
52-Week Low | $61.99 | $79.95 |
Enterprise Value | $2.94B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics (TMDX) trades at $73.47, down 0.69% with neutral technical signals. The stock shows strong profitability with 27% net margins and 45% ROE, though Q1 2026 earnings missed expectations. Recent strategic investment in European aviation logistics aims to expand the Organ Care System platform. Analyst consensus remains bullish with a $108.71 price target representing 48% upside potential.
Long-term growth prospects appear solid given TMDX's expanding transplant ecosystem, but near-term margin pressure from expansion investments and execution risks warrant caution. The company maintains competitive advantages in organ transplant logistics, though increased spending and competitive threats from alternatives like Strata Critical Medical present headwinds for shareholder returns.
VYMI trades at $100.23, down 0.65% on the day, with a bullish technical signal driven by moving averages and strong trend momentum (ADX 6-day at 60.71). The ETF offers a forward dividend of $1.26 payable June 23, 2026. Recent news highlights its role in diversifying away from U.S. tech, with Vanguard research suggesting international stocks may outperform over the next decade.
Outlook remains positive given its low 0.07% expense ratio, high dividend yield, and diversification benefits. Risks include currency fluctuations and global economic volatility. Analyst sentiment is favorable, emphasizing sustainable dividends and attractive valuations relative to U.S. markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Vanguard International High Dividend Yield ETF
VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →
